Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

Understanding Your Prognosis and IPI Score

At a Glance

The International Prognostic Index (IPI) is a clinical tool used to estimate diffuse large B-cell lymphoma (DLBCL) prognosis. It evaluates age, stage, LDH levels, performance status, and extranodal sites to guide treatment planning, but it does not dictate an individual's chance of a cure.

Once your diagnosis is confirmed, your doctor will use a series of clinical “clues” to estimate how the lymphoma might behave and how well you are likely to respond to treatment. The most common tool for this is the International Prognostic Index (IPI) [1].

Think of the IPI not as a crystal ball, but as a statistical “weather report.” Just as a meteorologist uses temperature and humidity to predict the likelihood of rain, doctors use these factors to categorize patients into groups [2][3]. While the IPI describes what happens to large groups of people, it cannot predict exactly what will happen to you as an individual [4].

The 5 Factors of the IPI

The standard IPI assigns one point for each of the following factors [1][5]:

  1. Age: Being over age 60 is considered a risk factor because older bodies sometimes handle intensive chemotherapy differently than younger ones [1].
  2. Stage: Having Stage III or IV disease (meaning the lymphoma is on both sides of your diaphragm or in distant organs) adds a point [1].
  3. LDH Level: Lactate Dehydrogenase (LDH) is a protein found in almost all body tissues. When cancer cells grow and divide quickly, they leak LDH into the bloodstream [6]. An elevated LDH level is a marker that the lymphoma is highly active [7][8].
  4. Performance Status: This is a measure of how well you can perform daily activities. Doctors use a scale to see if you are fully active, restricted in strenuous activity, or spend a significant amount of time in bed [1]. Note: Feeling awful or bedridden right now is common due to the untreated cancer, but your performance status often improves dramatically once the chemotherapy starts working [1].
  5. Extranodal Sites: This refers to cancer found in more than one organ outside of the lymph nodes (such as the bone marrow, liver, or lungs) [1][8].

Risk Categories

By adding these points (0 to 5), doctors place patients into risk categories [1].

  • Low Risk (0-1 points)
  • Low-Intermediate Risk (2 points)
  • High-Intermediate Risk (3 points)
  • High Risk (4-5 points)

Modern Variations: R-IPI and NCCN-IPI

As treatments have improved, the way we calculate these scores has evolved. You might hear your doctor mention these variations:

  • Revised IPI (R-IPI): This was created to better predict outcomes for patients receiving modern treatments like Rituximab [9][10].
  • NCCN-IPI: Developed by the National Comprehensive Cancer Network, this version is often considered more accurate for today’s patients because it looks at age and LDH levels with more precision [11][12].

Understanding Population Statistics

It is very common for patients to see a “High Risk” label and feel discouraged. However, it is vital to remember that these scores were built by looking at thousands of people in the past [2]. They do not account for your unique genetics, your willpower, or the very latest treatments that may not have been available when these statistics were first gathered [13][14]. Your score is a tool for your doctor to plan your treatment—it is not a limit on your potential for a cure [4][15].

For more details about treatments, proceed to Your First-Line Treatment Options.

Common questions in this guide

What is an IPI score for DLBCL?
The International Prognostic Index (IPI) is a tool doctors use to estimate how your lymphoma might behave and respond to treatment. It looks at clinical factors like your age and cancer stage to place patients into different risk categories.
What five factors make up the IPI score?
The standard IPI score evaluates your age, cancer stage, LDH protein levels in your blood, your performance status or ability to do daily activities, and whether the cancer has spread to multiple organs outside the lymph nodes.
What does an elevated LDH level mean for lymphoma?
Lactate Dehydrogenase (LDH) is a protein that leaks into the bloodstream when cancer cells grow quickly. An elevated LDH level is a marker indicating that the lymphoma is highly active.
What are the R-IPI and NCCN-IPI scores?
These are modern variations of the standard IPI score. They were developed to better predict outcomes for patients receiving newer treatments, looking at factors like age and LDH levels with more precision.
Does a high-risk IPI score mean my DLBCL cannot be cured?
No, a high-risk score is a tool for planning treatment, not a limit on your potential for a cure. IPI scores are based on historical population statistics and do not account for your unique genetics or the latest treatments available today.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current IPI score, and which version (Standard, R-IPI, or NCCN-IPI) are you using?
  2. 2.How did my LDH level compare to the 'normal' range, and what does that tell you about how active my lymphoma is?
  3. 3.Does my performance status or age change the way you'll approach the intensity of my treatment?
  4. 4.Beyond this score, what other personal factors in my health are you considering as we plan my care?
  5. 5.How often will we re-evaluate these markers (like LDH) to see if the treatment is working?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

    Seo S, Hong JY, Yoon S, et al.

    Oncotarget 2016; (7(47)):76934-76943 doi:10.18632/oncotarget.12734.

    PMID: 27764777
  2. 2

    Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective.

    Pieterse AH, Kunneman M, Engelhardt EG, et al.

    Psycho-oncology 2017; (26(7)):943-950 doi:10.1002/pon.4241.

    PMID: 27502561
  3. 3

    Exploring Key Elements of Surgical Shared Decision Making for Providers and Older Adults.

    Poles G, Erlick M, Zimmer A, Russell M

    MDM policy & practice 2025; (10(2)):23814683251382259 doi:10.1177/23814683251382259.

    PMID: 41179341
  4. 4

    Shared decision making in oncology: A model based on patients', health care professionals', and researchers' views.

    Bomhof-Roordink H, Fischer MJ, van Duijn-Bakker N, et al.

    Psycho-oncology 2019; (28(1)):139-146 doi:10.1002/pon.4923.

    PMID: 30346076
  5. 5

    Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma.

    Lee KR, Lee JO, Lee JS, Paik JH

    Journal of Cancer 2022; (13(15)):3598-3605 doi:10.7150/jca.67569.

    PMID: 36606193
  6. 6

    A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma.

    Wang Y, Wang X, Huang XY, et al.

    Cell reports. Medicine 2025; (6(11)):102452 doi:10.1016/j.xcrm.2025.102452.

    PMID: 41260205
  7. 7

    The multiple roles of LDH in cancer.

    Claps G, Faouzi S, Quidville V, et al.

    Nature reviews. Clinical oncology 2022; (19(12)):749-762 doi:10.1038/s41571-022-00686-2.

    PMID: 36207413
  8. 8

    Clinico-pathologic Profile of Filipino Patients Diagnosed with Diffuse Large B-Cell Lymphoma, Germinal Center or Non-germinal Center Subtype Treated in a Public Tertiary Hospital from 2016 to 2021.

    Cancio JEG, Damian KB, Villanueva EQ, et al.

    Acta medica Philippina 2025; (59(5)):58-64 doi:10.47895/amp.vi0.9688.

    PMID: 40438479
  9. 9

    A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.

    Jelicic J, Juul-Jensen K, Bukumiric Z, et al.

    European journal of haematology 2025; (114(1)):26-36 doi:10.1111/ejh.14301.

    PMID: 39257078
  10. 10

    Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.

    Gleeson M, Counsell N, Cunningham D, et al.

    British journal of haematology 2021; (192(6)):1015-1019 doi:10.1111/bjh.16691.

    PMID: 32436212
  11. 11

    Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

    Bishton MJ, Hughes S, Richardson F, et al.

    British journal of haematology 2016; (172(2)):246-54 doi:10.1111/bjh.13831.

    PMID: 26577576
  12. 12

    Validation of the International Prognostic Index and Subsequent Revisions for Diffuse Large B-Cell Lymphoma in Patients From the Middle East and North Africa Region.

    Alamer F, Alamir A, Alqahtani A, et al.

    Cureus 2020; (12(8)):e9620 doi:10.7759/cureus.9620.

    PMID: 32923221
  13. 13

    External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.

    Warnnissorn N, Kanitsap N, Niparuck P, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):1237-1245 doi:10.1080/16078454.2022.2147916.

    PMID: 36413354
  14. 14

    Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.

    Guo Y, Lian J, Chen Y, et al.

    Hematology (Amsterdam, Netherlands) 2025; (30(1)):2445395 doi:10.1080/16078454.2024.2445395.

    PMID: 39722597
  15. 15

    Patient and physician views of shared decision making in cancer.

    Tamirisa NP, Goodwin JS, Kandalam A, et al.

    Health expectations : an international journal of public participation in health care and health policy 2017; (20(6)):1248-1253 doi:10.1111/hex.12564.

    PMID: 28464430

This page explains DLBCL prognostic tools and the IPI score for educational purposes only. Always discuss your specific prognosis, risk factors, and test results with your oncologist.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.